We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Particle Size Not Cholesterol Determines Capacity of HDL to Reduce CVD

By LabMedica International staff writers
Posted on 16 Aug 2016
Results of a recent study suggested that the number and size of high-density lipoprotein (HDL) particles in the blood were better indicators of cardiovascular disease (CVD) risk than was the classical measurement of HDL-cholesterol.

To try to explain why treatments to elevate plasma high-density lipoprotein cholesterol (HDL-C) fail to reduce CVD risk, investigators at the Hebrew University of Jerusalem (Israel) recruited a study population comprising 504 Jerusalem residents (274 Arabs and 230 Jews). More...
The participants' HDL was measured and classified by NMR spectroscopy, and calcification in their coronary arteries (CAC), reflecting the overall burden of coronary atherosclerosis, was determined by multidetector helical CT-scanning.

Results revealed that HDL-C was not protectively associated with CAC, but that HDL particle number (HDL-P) was strongly protectively associated with CAC. Small and medium-sized HDL (MS-HDL-P) and HDL-P accounted for the protective effects of HDL-P. Large HDL-P and average HDL-P size were not significantly associated with CAC. Therefore, MS-HDL-P and HDL-P were better risk markers for CAC than the traditional HDL-C.

"Our findings indicate that HDL-P and MS-HDL-P are better independent markers of coronary artery disease, as reflected by coronary artery calcification, than HDL-C, at least in this bi-ethnic population of Israelis and Palestinians," said first author Dr. Chobufo Ditah, (from Cameroon) a master of public health student at the Hebrew University of Jerusalem. "These findings support previous reports, based on studies in other population groups, suggesting that small dense HDL particles are protectively associated with risk of coronary heart disease. The consistency of this finding in a new population of urban Arabs and Jews, using different disease outcomes and different separation methods, add more strength to those findings."

"With a better understanding of HDL's complexity and a better ability to measure its components, it is now possible to move past HDL-C to more refined measures that better reflect HDL's role in coronary heart disease risk. Based on the accumulating evidence, incorporation of MS-HDL-P or HDL-P into the routine prediction of coronary heart disease risk should be considered," said senior author Dr. Jeremy Kark, professor of epidemiology at the Hebrew University of Jerusalem.

The study was published in the August 2016 issue of the journal Atherosclerosis.

Related Links:
Hebrew University of Jerusalem


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Thyroid Test
Anti-Thyroid EIA Test
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.